Lv56
1044 积分 2022-08-12 加入
TYK2: an emerging therapeutic target in rheumatic disease
2天前
已完结
Trends in the drug target landscape for autoimmune diseases
2天前
已完结
Novel drug targets in 2024
2天前
已完结
Pancreatic cancer
2天前
已完结
Pancreatic cancer
2天前
已完结
In Vitro ADME Profiling of PROTACs: Successes, Challenges, and Lessons Learned from Analysis of Clinical PROTACs from a Diverse Physicochemical Space
2天前
已完结
Targeted protein degradation for cancer therapy
3天前
已完结
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
4天前
已完结
HER2 testing: evolution and update for a companion diagnostic assay
6天前
已完结
The impact of accelerated drug marketing registration procedures on the review and approval of new drugs in China
7天前
已完结
皖公网安备34019202002308
